Shares of Dr Reddy's Laboratories Ltd. will be of interest on Wednesday as it marks the last session for investors to buy shares to qualify for receiving the dividend before the stock goes ex/record-date.
For a dividend, investors should note the record date that determines shareholder eligibility.
Under India's T+1 settlement cycle, shares purchased on the record date itself will not qualify for the dividend payment. Hence, if the record date of a dividend stock is July 10, then shares must be purchased by July 9.
The ex-dividend date, which typically coincides with the record date, marks when the share price adjusts to reflect the upcoming payout.
Dr Reddy's Labs will pay a final dividend of Rs 8 per share for the financial year 2025. The company will distribute Rs 667 crore to nearly 4.6 lakh shareholders.
Retail investors holding nominal share capital up to Rs 2 lakh own 8.12% equity in the drugmaker. The payout for this portion will be around Rs 54 crore.
The company will announce its June quarter results on July 23.
Dr. Reddy's Laboratories along with shares of companies like Gland Pharma Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Lupin Ltd., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Cipla Ltd. and Torrent Pharmaceuticals Ltd. will be in focus after US President Donald Trump threatened to slap 200% tariffs on pharmaceutical products.
The announcement came in a press briefing following a Cabinet meeting, where he also announced a 50% tariff on copper imports.
Trump's threat of a 200% tariff on pharmaceutical products can have severe implications on Indian drugmakers, as exports to the US form a significant share of their overall sales.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
